This article is for educational and research purposes only. BodyHackGuide does not sell, distribute, or endorse human consumption of any compound. Neither BPC-157 nor TB-500 is FDA approved. Always consult a qualified healthcare provider before considering any research peptide.
The Wolverine Stack is the most widely discussed peptide combination in the biohacking and recovery community. Named after the Marvel character known for near-instant regeneration, this protocol pairs BPC-157 with TB-500 to target tissue repair through two entirely different biological pathways simultaneously.
Neither peptide is FDA approved for human use. What follows is an evidence-based breakdown of the published research, proposed mechanisms, commonly referenced protocols, and practical considerations for anyone researching these compounds. Every claim is backed by a PubMed citation you can verify yourself.
What Is the Wolverine Stack?
The Wolverine Stack refers to the concurrent use of two research peptides ā BPC-157 (Body Protection Compound-157) and TB-500 (a synthetic fragment of Thymosin Beta-4) ā in a single recovery protocol. The theory behind the combination is straightforward: each peptide promotes tissue repair through fundamentally different mechanisms, so using both creates a broader, more comprehensive healing response than either compound alone.
BPC-157 is a 15-amino acid peptide derived from a protective protein found naturally in human gastric juice. It works primarily through local mechanisms ā promoting angiogenesis (new blood vessel formation), modulating the nitric oxide system, and upregulating growth factor receptors at the injury site.1
TB-500 is a 43-amino acid peptide that mirrors the active region of thymosin beta-4, an actin-sequestering protein found in nearly all human cells. It operates systemically ā promoting cell migration, reducing inflammation through NF-kB downregulation, and facilitating cytoskeletal remodeling across the entire body.2
The core logic of the Wolverine Stack:
BPC-157 handles local repair at the injury site (blood vessels, growth factors, collagen). TB-500 handles systemic repair across the body (cell migration, inflammation, tissue remodeling). Together, they cover both sides of the healing equation.
For a detailed head-to-head comparison of these two peptides as standalone compounds, see our comprehensive guide: BPC-157 vs TB-500 ā Head-to-Head Comparison.
How BPC-157 Works
BPC-157 (Body Protection Compound-157) is a stable gastric pentadecapeptide ā a 15-amino acid fragment derived from a larger protein (BPC) naturally present in human gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Unlike many peptides, BPC-157 is remarkably stable in gastric acid, which is unusual for a short-chain peptide and contributes to its research interest for oral administration.3
The mechanisms of BPC-157 are multi-pathway. Published research has identified several key actions:
Angiogenesis Promotion
BPC-157 upregulates VEGFR2 (vascular endothelial growth factor receptor 2), promoting the formation of new blood vessels at injury sites. This increased vascularization delivers more oxygen and nutrients to damaged tissue, accelerating repair.1
Nitric Oxide System Modulation
BPC-157 interacts with the nitric oxide (NO) system in a balancing manner ā it can counteract both NO-excess and NO-deficiency states. This bidirectional modulation helps normalize vasodilation, blood flow, and inflammatory signaling at the tissue level.4
Growth Factor Modulation
BPC-157 upregulates EGR-1 (early growth response protein 1) gene expression, which in turn activates downstream growth factors including EGF, TGF-Ī², and their associated receptors. This cascade accelerates collagen deposition, fibroblast activity, and tissue remodeling.5
Gastroprotective Activity
As a compound derived from gastric juice, BPC-157 demonstrates strong cytoprotective effects on GI mucosa. Animal studies show it accelerates healing of gastric ulcers, esophageal lesions, and inflammatory bowel damage, and counters NSAID-induced gut injury.3
For a deeper dive into BPC-157 research, reconstitution, and dosing, see the BPC-157 compound profile and our BPC-157 reconstitution guide.
How TB-500 Works
TB-500 is a synthetic version of the active region of thymosin beta-4 (TĪ²4), a 43-amino acid peptide found in virtually all human and animal cells. Thymosin beta-4 is one of the most abundant intracellular proteins, and it plays a central role in cytoskeletal dynamics ā the structural scaffolding that determines how cells move, divide, and organize.2
Actin Sequestration
TB-500 binds to G-actin monomers, preventing premature polymerization into filaments. This creates a reserve pool of actin that can be rapidly deployed when cells need to migrate to wound sites or restructure their cytoskeletons for repair.6
Cell Migration Promotion
By modulating the actin cytoskeleton, TB-500 promotes the migration of keratinocytes, endothelial cells, and other repair cells toward injury sites. This is a critical step in wound healing ā cells must physically travel to the damage before they can begin repair.7
Anti-Inflammatory Action
TB-500 downregulates the NF-kB inflammatory pathway, one of the master switches controlling the body's inflammatory response. This systemic anti-inflammatory effect helps reduce chronic inflammation that can delay healing and cause ongoing tissue damage.2
Cardiac Tissue Repair
Thymosin beta-4 has some of the strongest preclinical evidence of any peptide for cardiac repair. Studies show it can activate cardiac progenitor cells and promote myocardial repair after ischemic injury, making it a subject of ongoing clinical research.7
For the full research profile, see the TB-500 compound profile.
Why Combine BPC-157 and TB-500?
The rationale for the Wolverine Stack is not about redundancy ā it is about complementary coverage. BPC-157 and TB-500 address tissue repair through mechanisms that do not overlap, which means combining them potentially covers more of the healing cascade than either peptide alone.
Different mechanisms, no competition. BPC-157 modulates NO/VEGFR2 pathways while TB-500 regulates actin dynamics and NF-kB. They bind to different targets and do not compete for the same receptors.
Local + systemic coverage. BPC-157 excels at localized repair (inject near the injury). TB-500 distributes systemically regardless of injection site. Together, you address both the specific injury and the body's overall inflammatory and repair state.
Different half-lives create sustained action. BPC-157 has a shorter half-life requiring more frequent dosing (1-2x daily). TB-500 has a longer biological half-life, dosed only 2x per week. This creates overlapping windows of therapeutic activity.
Complementary tissue targets. BPC-157 has the strongest evidence for tendon, ligament, and GI tissue. TB-500 has the strongest evidence for cardiac, dermal, and systemic inflammatory conditions. The stack covers a wider range of injury types.
It is important to note that while the theoretical rationale is sound and community use is widespread, there are no published studies that specifically examine the BPC-157 + TB-500 combination in a controlled setting. The synergy hypothesis is based on the independent mechanisms of each peptide and community-reported outcomes.
BPC-157 vs TB-500 ā Side-by-Side Comparison
This table summarizes the key differences between the two peptides in the Wolverine Stack. For a full deep-dive comparison, see BPC-157 vs TB-500 Head-to-Head.
| Property | BPC-157 | TB-500 |
|---|---|---|
| Full Name | Body Protection Compound-157 | Thymosin Beta-4 Fragment |
| Amino Acids | 15 | 43 |
| Primary Mechanism | NO modulation, VEGFR2 upregulation, EGR-1 activation | Actin sequestration, NF-kB downregulation, cell migration |
| Route | Subcutaneous injection or oral | Subcutaneous or intramuscular injection |
| Half-Life | Shorter (dose 1-2x/day) | Longer (dose 2x/week) |
| Best Use Case | Tendon, ligament, GI healing, localized injury | Cardiac repair, systemic inflammation, wound healing |
| Typical Dose Range | 250-500 mcg, 1-2x/day | 2-5 mg, 2x/week |
| Oral Bioavailability | Yes (gastric acid stable) | No (injection only) |
| PubMed Studies | 90+ | 60+ |
The Research Protocol
The following protocol represents the most commonly referenced Wolverine Stack dosing schedule in the research community. It is divided into two phases: a loading phase (higher frequency to build tissue levels) and a maintenance phase (reduced frequency to sustain effects).
These are research-referenced protocols, not medical prescriptions.
No human clinical trials have established optimal dosing for BPC-157 + TB-500 combination use. The doses below are derived from preclinical studies and community-reported protocols. Always consult a healthcare provider.
Phase 1: Loading (Weeks 1-4)
The loading phase uses higher-frequency dosing to rapidly build tissue concentrations of both peptides. TB-500 in particular benefits from a loading phase due to its mechanism of building an actin monomer reserve in tissues.6
| Peptide | Dose | Frequency | Route | Injection Site |
|---|---|---|---|---|
| BPC-157 | 250-500 mcg | 2x per day | Subcutaneous | Near injury site |
| TB-500 | 2-5 mg | 2x per week | Subcutaneous | Abdomen, thigh, or deltoid |
Phase 2: Maintenance (Weeks 5-12)
After the loading phase, dosing frequency is typically reduced. BPC-157 may be dropped to once daily and TB-500 to once per week, depending on the response and the severity of the injury being addressed.
| Peptide | Dose | Frequency | Route | Notes |
|---|---|---|---|---|
| BPC-157 | 250-500 mcg | 1x per day | Subcutaneous | Can continue near injury or switch to abdomen |
| TB-500 | 2-5 mg | 1x per week | Subcutaneous | Systemic ā any subq site |
Cycling recommendation: Most community protocols suggest running the Wolverine Stack for 8-12 weeks, followed by 4 weeks off before repeating if needed. This conservative approach accounts for the lack of long-term human safety data on either compound.
For more on peptide recovery protocols, see our guide to the best peptides for recovery.
Reconstitution Quick Reference
Both BPC-157 and TB-500 come as lyophilized (freeze-dried) powders that must be reconstituted with bacteriostatic water before use. Proper reconstitution is critical ā incorrect technique can destroy the peptide or introduce contamination.
BPC-157 Reconstitution Calculator
Enter your vial size, desired dose, and get exact bacteriostatic water amounts and syringe markings.
Open calculatorTB-500 Reconstitution Calculator
Enter your vial size, desired dose, and get exact bacteriostatic water amounts and syringe markings.
Open calculatorKey reconstitution rules for both peptides:
- Use only bacteriostatic water (BAC water) ā never sterile water, saline, or tap water.
- Direct the stream of water down the inside wall of the vial ā never spray directly onto the peptide cake.
- Swirl gently to dissolve. Never shake vigorously ā this can denature the peptide.
- Store reconstituted peptides refrigerated at 2-8Ā°C (36-46Ā°F). Do not freeze reconstituted solutions.
- Use reconstituted BPC-157 within 21-28 days. TB-500 within 21 days.
For detailed step-by-step instructions, see our complete peptide reconstitution guide and our peptide storage guide.
Sourcing & Quality
Peptide quality is arguably the most important variable in any research protocol. BPC-157 and TB-500 are unregulated research chemicals, which means the market includes both legitimate high-purity products and low-quality or counterfeit material. The difference between a 99%+ purity peptide and a contaminated one can be the difference between meaningful research results and wasted effort ā or worse.
Non-Negotiable Quality Checks
Third-party Certificate of Analysis (COA) for every batch ā verifying identity (mass spectrometry), purity (HPLC ā„99%), and endotoxin levels.
COA must be from an independent lab, not the vendor's own facility.
Vendor should provide batch-specific COAs, not generic certificates.
Check for proper lyophilization (white or off-white powder cake, not liquid or discolored).
Avoid vendors who do not publish COAs or refuse to provide them on request.
Safety & Side Effects
Neither BPC-157 nor TB-500 has been through human clinical trials (as of April 2026). All safety data comes from preclinical animal studies and community self-reports. This is a significant limitation. Here is what the current evidence shows:
BPC-157 Safety Profile
BPC-157 has demonstrated a remarkably clean safety profile in over 90 animal studies. No lethal dose (LD1) has been established in toxicology studies ā researchers have been unable to find a dose high enough to cause mortality in rodent models.3 This is unusual for a biologically active peptide. Community-reported side effects are generally mild and uncommon:
- -Injection site redness, swelling, or minor pain (most common, typically resolves within hours)
- -Mild nausea (more common with oral administration)
- -Transient lightheadedness (rare, possibly related to vasodilation/NO modulation)
- -Mild headache (uncommon)
TB-500 Safety Profile
TB-500 (thymosin beta-4) has been used in equine veterinary medicine for years and has been the subject of multiple clinical trials for wound healing and cardiac repair in humans (under the name "Timbetasin" or "RGN-352"). Its safety profile is generally considered favorable:8
- -Injection site reactions (redness, mild swelling ā the most commonly reported issue)
- -Temporary fatigue or lethargy in the first 1-2 days after injection (uncommon)
- -Mild flu-like symptoms during loading phase (uncommon, typically resolves)
- -Headache (rare)
When to stop immediately:
- - Severe injection site swelling, redness spreading beyond 2 inches, or signs of infection (warmth, pus, streaking)
- - Allergic reaction signs: hives, difficulty breathing, swelling of face or throat
- - Persistent fever above 101Ā°F (38.3Ā°C)
- - Any symptom that is new, severe, or concerning
Seek medical attention immediately if you experience any of the above.
A historical concern regarding thymosin beta-4 and cancer promotion has been raised but not supported by the current body of evidence. A 2010 review found no causal relationship between TĪ²4 administration and tumor growth.9 However, as a precaution, individuals with active malignancies should avoid TB-500 until more definitive data is available.
Frequently Asked Questions
Related Resources
Disclaimer: This content is for research and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Neither BPC-157 nor TB-500 is approved by the FDA for any human use. Both are classified as research chemicals. Use of research-grade peptides carries inherent risks including contamination, inaccurate dosing, and unknown long-term effects. Always consult a qualified healthcare provider before using any research compound. BodyHackGuide does not sell, supply, or endorse the purchase of any controlled or investigational substance.
Last updated: April 13, 2026 Ā· Written by Choncho Ā· BodyHackGuide Research Team
Independent researcher and founder of BodyHackGuide. Obsessed with evidence-based biohacking, peptide science, and nootropic protocols. Every recommendation is backed by PubMed citations and real-world testing.
Was this page helpful?